Drugs / WSK-V101
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05911048 Comparator | Dec 2024 → Jun 2025 overdue | COVID-19 | WestVac Biopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WSK-V101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05911048 ↗ |
| Known as | Recombinant COVID-19 vaccine (Sf9 Cell) | “Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)” NCT05911048 ↗ |
| Modality | Vaccine | “Recombinant COVID-19 vaccine (Sf9 Cell)” NCT05911048 ↗ |